177 related articles for article (PubMed ID: 31837226)
1. The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease.
Verbeke F; Siwy J; Van Biesen W; Mischak H; Pletinck A; Schepers E; Neirynck N; Magalhães P; Pejchinovski M; Pontillo C; Lichtinghagen R; Brand K; Vlahou A; De Bacquer D; Glorieux G
Nephrol Dial Transplant; 2021 Apr; 36(5):811-818. PubMed ID: 31837226
[TBL] [Abstract][Full Text] [Related]
2. Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.
Rodríguez-Ortiz ME; Pontillo C; Rodríguez M; Zürbig P; Mischak H; Ortiz A
Sci Rep; 2018 Oct; 8(1):15940. PubMed ID: 30374033
[TBL] [Abstract][Full Text] [Related]
3. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression.
Critselis E; Lambers Heerspink H
Nephrol Dial Transplant; 2016 Feb; 31(2):249-54. PubMed ID: 25791724
[TBL] [Abstract][Full Text] [Related]
4. Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.
Currie GE; von Scholten BJ; Mary S; Flores Guerrero JL; Lindhardt M; Reinhard H; Jacobsen PK; Mullen W; Parving HH; Mischak H; Rossing P; Delles C
Cardiovasc Diabetol; 2018 Apr; 17(1):50. PubMed ID: 29625564
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
Critselis E; Vlahou A; Stel VS; Morton RL
Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
[TBL] [Abstract][Full Text] [Related]
6. CKD273, a new proteomics classifier assessing CKD and its prognosis.
Argilés Á; Siwy J; Duranton F; Gayrard N; Dakna M; Lundin U; Osaba L; Delles C; Mourad G; Weinberger KM; Mischak H
PLoS One; 2013; 8(5):e62837. PubMed ID: 23690958
[TBL] [Abstract][Full Text] [Related]
7. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
8. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
Lindhardt M; Persson F; Oxlund C; Jacobsen IA; Zürbig P; Mischak H; Rossing P; Heerspink HJL
Nephrol Dial Transplant; 2018 Feb; 33(2):296-303. PubMed ID: 28064163
[TBL] [Abstract][Full Text] [Related]
9. A urinary proteome-based classifier for the early detection of decline in glomerular filtration.
Pontillo C; Jacobs L; Staessen JA; Schanstra JP; Rossing P; Heerspink HJL; Siwy J; Mullen W; Vlahou A; Mischak H; Vanholder R; Zürbig P; Jankowski J
Nephrol Dial Transplant; 2017 Sep; 32(9):1510-1516. PubMed ID: 27387473
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial.
Curovic VR; Eickhoff MK; Rönkkö T; Frimodt-Møller M; Hansen TW; Mischak H; Rossing P; Ahluwalia TS; Persson F
Diabetes Care; 2022 Nov; 45(11):2662-2668. PubMed ID: 35998283
[TBL] [Abstract][Full Text] [Related]
11. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.
Oellgaard J; Gæde P; Persson F; Rossing P; Parving HH; Pedersen O
J Diabetes Complications; 2018 Dec; 32(12):1133-1140. PubMed ID: 30282584
[TBL] [Abstract][Full Text] [Related]
12. Association of the chronic kidney disease urinary proteomic predictor CKD273 with clinical risk factors of graft failure in kidney allograft recipients.
Rambabova-Bushljetik I; Metzger J; Siwy J; Dohcev S; Bushljetikj O; Filipce V; Trajceska L; Mischak H; Spasovski G
Nephrol Dial Transplant; 2022 Sep; 37(10):2014-2021. PubMed ID: 34634117
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.
Tofte N; Lindhardt M; Adamova K; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Kooy A; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Ruggenenti PL; Rutters F; Rychlík I; Spasovski G; Speeckaert M; Trillini M; von der Leyen H; Rossing P
Diabet Med; 2018 Oct; 35(10):1375-1382. PubMed ID: 29781558
[TBL] [Abstract][Full Text] [Related]
14. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.
Siwy J; Schanstra JP; Argiles A; Bakker SJ; Beige J; Boucek P; Brand K; Delles C; Duranton F; Fernandez-Fernandez B; Jankowski ML; Al Khatib M; Kunt T; Lajer M; Lichtinghagen R; Lindhardt M; Maahs DM; Mischak H; Mullen W; Navis G; Noutsou M; Ortiz A; Persson F; Petrie JR; Roob JM; Rossing P; Ruggenenti P; Rychlik I; Serra AL; Snell-Bergeon J; Spasovski G; Stojceva-Taneva O; Trillini M; von der Leyen H; Winklhofer-Roob BM; Zürbig P; Jankowski J
Nephrol Dial Transplant; 2014 Aug; 29(8):1563-70. PubMed ID: 24589724
[TBL] [Abstract][Full Text] [Related]
15. A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension.
Lin L; Wang C; Ren J; Mei M; Zheng L; Yang J
J Hypertens; 2023 Aug; 41(8):1306-1312. PubMed ID: 37199562
[TBL] [Abstract][Full Text] [Related]
16. Urinary peptidomic biomarkers of renal function in heart transplant recipients.
Huang QF; Zhang ZY; Van Keer J; Trenson S; Nkuipou-Kenfack E; Yang WY; Thijs L; Vanhaecke J; Van Aelst LNL; Van Cleemput J; Janssens S; Verhamme P; Mischak H; Staessen JA
Nephrol Dial Transplant; 2019 Aug; 34(8):1336-1343. PubMed ID: 29982668
[TBL] [Abstract][Full Text] [Related]
17. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease.
Pontillo C; Mischak H
Clin Kidney J; 2017 Apr; 10(2):192-201. PubMed ID: 28694965
[TBL] [Abstract][Full Text] [Related]
18. Carotid intima-media thickness is an independent predictor of all-cause mortality and cardiovascular morbidity in patients with diabetes mellitus type 2 and chronic kidney disease.
Roumeliotis A; Roumeliotis S; Panagoutsos S; Theodoridis M; Argyriou C; Tavridou A; Georgiadis GS
Ren Fail; 2019 Nov; 41(1):131-138. PubMed ID: 30909780
[TBL] [Abstract][Full Text] [Related]
19. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Papademetriou V; Lovato L; Tsioufis C; Cushman W; Applegate WB; Mottle A; Punthakee Z; Nylen E; Doumas M;
Am J Nephrol; 2017; 45(2):136-145. PubMed ID: 27992863
[TBL] [Abstract][Full Text] [Related]
20. The urinary proteome as correlate and predictor of renal function in a population study.
Gu YM; Thijs L; Liu YP; Zhang Z; Jacobs L; Koeck T; Zürbig P; Lichtinghagen R; Brand K; Kuznetsova T; Olivi L; Verhamme P; Delles C; Mischak H; Staessen JA
Nephrol Dial Transplant; 2014 Dec; 29(12):2260-8. PubMed ID: 24981581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
